Literature DB >> 28651328

Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.

Y Tomita1, D Sueta2, Y Kakiuchi3, S Saeki3, K Saruwatari3, S Sakata3, T Jodai3, Y Migiyama3, K Akaike3, S Hirosako3, K Fujisue2, S Yamamura2, S Miyazaki2, S Takashio2, Y Izumiya2, K Nakamura3, K Tsujita2, H Ichiyasu3, K Fujii3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28651328     DOI： 10.1093/annonc/mdx326

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  21 in total

1.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 2.  Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.

Authors:  Marion Ferreira; Eric Pichon; Delphine Carmier; Emilie Bouquet; Cécile Pageot; Theodora Bejan-Angoulvant; Marion Campana; Emmanuelle Vermes; Sylvain Marchand-Adam
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

3.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Authors:  Federico Nichetti; Francesca Ligorio; Emma Zattarin; Diego Signorelli; Arsela Prelaj; Claudia Proto; Giulia Galli; Antonio Marra; Giulia Apollonio; Luca Porcu; Filippo de Braud; Giuseppe Lo Russo; Roberto Ferrara; Marina Chiara Garassino
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

4.  Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.

Authors:  Xiaoying Sun; Raheleh Roudi; Ting Dai; Shangya Chen; Bin Fan; Hongjin Li; Yaqiong Zhou; Min Zhou; Bo Zhu; Chengqian Yin; Bin Li; Xin Li
Journal:  BMC Cancer       Date:  2019-06-10       Impact factor: 4.430

5.  A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.

Authors:  Takayuki Jodai; Chieko Yoshida; Ryo Sato; Yosuke Kakiuchi; Nahoko Sato; Shinji Iyama; Tomoko Kimura; Koichi Saruwatari; Sho Saeki; Hidenori Ichiyasu; Kazuhiko Fujii; Yusuke Tomita
Journal:  Immun Inflamm Dis       Date:  2018-11-21

Review 6.  Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.

Authors:  Yu-Wen Zhou; Ya-Juan Zhu; Man-Ni Wang; Yao Xie; Chao-Yue Chen; Tao Zhang; Fan Xia; Zhen-Yu Ding; Ji-Yan Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 7.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

8.  The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.

Authors:  Koichi Saruwatari; Ryo Sato; Shunya Nakane; Shinya Sakata; Koutaro Takamatsu; Takayuki Jodai; Remi Mito; Yuko Horio; Sho Saeki; Yusuke Tomita; Takuro Sakagami
Journal:  Cancers (Basel)       Date:  2019-01-24       Impact factor: 6.639

Review 9.  Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Authors:  Valli De Re; Laura Caggiari; Ombretta Repetto; Lara Mussolin; Maurizio Mascarin
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

Review 10.  Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem.

Authors:  Kikkie Poels; Suzanne I M Neppelenbroek; Marie José Kersten; M Louisa Antoni; Esther Lutgens; Tom T P Seijkens
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.